Biotech Moderna rallies 13% on sales beat and new vaccine launch hopes
Better than expected Q1 sales and narrower lossCovid vaccine sales plunged 90% year on yearRSV vaccine expected to be approvedUS biotechnology firm Moderna (MRNA:NASDAQ) surged 13% after reporting a smaller than expected quarterly loss and reaffirming the timeline for expected regulatory approval of its RSV (respiratory syncytial virus) vaccine.Management said it expects the regulator to announce